Enteric fever, commonly known as typhoid fever, is a systemic infection primarily caused by Salmonella Typhi and Salmonella Paratyphi A, B, and C. The disease presents a significant health challenge, particularly in areas with inadequate sanitation and poor access to clean drinking water. This article provides an in-depth guide to the effective management of enteric fever.
Salmonella Typhi and Paratyphi are the causative organisms of enteric fever. These bacteria are transmitted via the fecal-oral route, often through contaminated food or water. High-risk areas include South Asia, Africa, and parts of South America. Travelers to these regions are particularly at risk.
Patients typically present with high-grade fever, malaise, abdominal discomfort, and constipation or diarrhea. In severe cases, complications such as intestinal perforation, encephalopathy, or myocarditis may occur. Early diagnosis is critical to preventing these complications.
Diagnosis of enteric fever primarily involves blood culture, bone marrow culture, or stool culture. Serological tests like Widal test are also used, but they have lower sensitivity and specificity. Molecular methods, such as PCR, are increasingly being used for rapid and accurate diagnosis.
Antibiotic therapy is the cornerstone of treatment. Choice of antibiotic is guided by local susceptibility patterns. Fluoroquinolones, third-generation cephalosporins, and azithromycin are commonly used. In resistant cases, carbapenems may be considered. Supportive care includes hydration and antipyretics.
Preventive measures include safe food and water practices, improved sanitation, and vaccination. Two vaccines are currently available: the oral live-attenuated vaccine (Ty21a) and the injectable polysaccharide vaccine (ViCPS).
In conclusion, enteric fever remains a significant global health challenge. Effective management involves early diagnosis, appropriate antibiotic therapy, and preventive measures. Ongoing research into better diagnostic tools and more effective vaccines is crucial for controlling this disease.
1.
Trial Supports Ivonescimab and Chemo for NSCLC Survival
2.
Cancer "Tidal Wave" Prediction: Not Cigarette-Based, Either! Wary Stories Regarding Cannabis and Cancer.
3.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
4.
Silibinin is a novel and ancient molecule that highlights the significance of integrated therapies for cancer.
5.
Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?
1.
Unlocking the Power of Hematocrit: Exploring the Benefits of Blood Cell Counts
2.
Unpacking Chordoma: Understanding the Rare Cancer and its Treatment Options
3.
Colorectal Cancer Incidence Trends: A Growing Concern in 2024 and 2025
4.
Uncovering the Mysteries of the RDW Blood Test
5.
The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Complexities of Ph Negative ALL - Part II
2.
The Reign of the CROWN Trial and the Dawn of a New Era in Frontline Management
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
5.
Navigating the Complexities of Ph Negative ALL - Part XIV
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation